EUCTR2007-007174-35-DE进行中（未招募）不适用
Randomized, placebo-controlled phase-IV clinical trial for the application of physostigmine salicylate for an early post-operative restoration of vigilance and cognition after cardiopulmonary bypass surgery: Recording of additional analgetic and anti-inflammatory active components.
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •-Elective cardiosurgery (bypass surgery / prosthetic heart valve or reconstruction of the heat valve)
- •-ASA classification II and III
- •-Being of legal age
- •-Written informed consent to participate in the clinical trial
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.Known contraindication to physostigmine salicylate, such as bronchial asthma or hypersensitivity to sulfites
- •2.Stenoses of the intestinal tract and the bile ducts
- •3.Pregnancy
- •4.Neurological diseases
- •5.Left ventricular ejection fraction < 40 %
- •6.Simultaneous participation in other clinical trials or participation in other clinical trials within the last 30 days.
研究者
相似试验
已完成
4 期
Phase IV study, randomized, placebo-controlled for the evaluation of efficacy and tolerability of arginine aspartate in patients with moderate to severe fatigueModerate to severe fatigueOther - Conditions of unknown or disputed aetiology (such as chronic fatigue syndrome/myalgic encephalomyelitis)ACTRN12608000535370ikkho Zydus60
进行中（未招募）
不适用
Study about the high flow and conventional oxigen therapy in patients with severe acute respiratory failure.EUCTR2012-001671-36-ESFundación para la Investigación Biomédica
进行中（未招募）
1 期
RoActemra® (tocilizumab) plus methotrexate (MTX) in stable dosage in comparison with RoActemra® plus reducing (tapering) MTX dosages in patients with severe rheumatoid arthritis (RA) that have inadequate responded to a trial of two disease modifying anti-rheumatic drugs (DMARDs), including MTX and have not been previously treated with a biologic agent, such as a TNF inhibitor.Adult Rheumatoid Arthritis (RA)MedDRA version: 20.0 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disordersEUCTR2011-005260-20-GBRoche Products Limited427
进行中（未招募）
1 期
MK-8228 vs. Placebo in Prevention of CMV infection in HSCT RecipientsClinically significant CMV infectionMedDRA version: 19.0Level: LLTClassification code 10009703Term: CMV infectionSystem Organ Class: 100000004862EUCTR2013-003831-31-LTMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc540
进行中（未招募）
1 期
MK-8228 vs. Placebo in Prevention of CMV infection in HSCT RecipientsClinically significant CMV infectionEUCTR2013-003831-31-ESMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc540